KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Free Cash Flow: 2011-2024

Historic Free Cash Flow for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$24.0 million.

  • Esperion Therapeutics' Free Cash Flow rose 87.92% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$93.3 million, marking a year-over-year decrease of 257.77%. This contributed to the annual value of -$24.0 million for FY2024, which is 82.31% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Free Cash Flow of -$24.0 million as of FY2024, which was up 82.31% from -$135.5 million recorded in FY2023.
  • Over the past 5 years, Esperion Therapeutics' Free Cash Flow peaked at -$24.0 million during FY2024, and registered a low of -$263.8 million during FY2021.
  • Over the past 3 years, Esperion Therapeutics' median Free Cash Flow value was -$135.5 million (recorded in 2023), while the average stood at -$111.4 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 206.59% in 2021, then surged by 82.31% in 2024.
  • Esperion Therapeutics' Free Cash Flow (Yearly) stood at -$86.0 million in 2020, then tumbled by 206.59% to -$263.8 million in 2021, then skyrocketed by 33.73% to -$174.8 million in 2022, then rose by 22.50% to -$135.5 million in 2023, then soared by 82.31% to -$24.0 million in 2024.